optiprep fraction (CEM Corporation)
Structured Review

Optiprep Fraction, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/optiprep fraction/product/CEM Corporation
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness"
Article Title: High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness
Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology
doi: 10.1152/ajplung.00405.2009
Figure Legend Snippet: Analysis of CD44 and caveolin-1 regulation of high-molecular-weight hyaluronan (HMW-HA) binding to human pulmonary endothelial cells (EC). A: EC were grown to confluency and serum-starved for 1 h, and Triton X-100-soluble, Triton X-100-insoluble, and OptiPrep fractions were prepared. The 20% OptiPrep fraction represents the caveolin-enriched microdomain (CEM) fraction. Fractions were run on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-caveolin-1 (a), anti-fibrillarin (b), anti-cyclooxygenase (COX) IV (c), anti-lysosomal-associated membrane glycoprotein 2 precursor (LAMP2b, d), anti-Golgi reassembly stacking protein 65 (GRASP65, e), or anti-VEGF receptor (anti-VEGFR, f). B: EC were grown to confluency, serum-starved for 1 h, and either left untreated (control) or treated with 100 nM HMW-HA (5 min) or the CEM-abolishing cholesterol-depletion agent methyl-β-cyclodextrin (MβCD, 5 mM) for 1 h prior to 100 nM HMW-HA treatment (5 min). Cellular material was solublized in 4°C 1% Triton X-100, and soluble and insoluble fractions were obtained. Triton X-100-insoluble fraction was overlaid with 60%, 40%, 30%, and 20% OptiPrep and centrifuged at 35,000 rpm in an SW60 rotor for 12 h at 4°C. Triton X-100-soluble material and OptiPrep fractions were run on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-caveolin-1 (a), anti-CD44s (IM-7, standard domain, b), or anti-VEGF receptor 2 (anti-VEGFR2, c) antibody. The 20% OptiPrep fraction is the CEM fraction. Experiments were performed in triplicate, with highly reproducible findings, and representative data are shown. C: immunoblot analysis of small interfering RNA (siRNA)-treated or untreated human EC. Cellular lysates from untransfected (control, no siRNA), scramble siRNA (siRNA that does not target any known human mRNA), caveolin-1 siRNA, or CD44 siRNA transfection were analyzed using immunoblotting with anti-caveolin-1 (a), anti-CD44 (IM-7, b), or anti-actin (c) antibody. Experiments were performed in triplicate, each with similar results, and representative data are shown. D: quantitation of fluorescein-conjugated HMW-HA binding to scramble siRNA-, annexin A11 siRNA-, CD44 siRNA-, or caveolin-1 siRNA-treated EC. Fluorescein-conjugated HMW-HA (100 nM) was added for 15 min to EC in serum-free medium, cells were washed 3 times in serum-free medium, and fluorescence intensity was quantified. Cells were counted utilizing a hemocytometer.
Techniques Used: High Molecular Weight, Binding Assay, SDS Page, Membrane, Control, Western Blot, Small Interfering RNA, Transfection, Quantitation Assay, Fluorescence
Figure Legend Snippet: Role of HMW-HA-induced recruitment of annexin A2 and protein S100-A10 to human EC CEM. A: HMW-HA induces caveolin-1 redistribution to EC-EC junctions. Human EC were grown to confluency, serum-starved for 1 h, and either left untreated (control) or treated with 100 nM HMW-HA (15 min), fixed in 4% paraformaldehyde, and stained with anti-caveolin-1 antibody, anti-vascular endothelial (VE)-cadherin antibody, or 4′,6-diamidino-2-phenylindole (DAPI). Overlay is a merged image of caveolin-1, VE-cadherin, and DAPI fluorescence, with yellow color indicating colocalization of caveolin-1 and VE-cadherin. B and C: EC were grown to confluency, serum-starved for 1 h, and either left untreated (control) or treated with 100 nM HMW-HA (5 min) and CEM fractions (20% OptiPrep layer). B: CEM fractions were run on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-annexin A2 (a), anti-protein S100-A10 (b), anti-filamin A (c), anti-filamin B (d), or anti-caveolin-1 (e) antibody. Experiments were performed in triplicate, with highly reproducible findings, and representative data are shown. C: CEM fractions were solublized in immunoprecipitation (Ippt) buffer and immunoprecipitated with anti-annexin A2 antibody. Resulting immunobeads were run on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-phosphotyrosine (a) or anti-annexin A2 (b) antibody. Experiments were performed in triplicate, with highly reproducible findings, and representative data are shown. D: EC were treated with no siRNA (control), scramble siRNA, annexin A2 siRNA, or protein S100-A10 siRNA for 48 h. EC lysates were obtained and run on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-annexin A2 (a), anti-protein S100-A10 (b), or anti-actin (c) antibody. Experiments were performed in triplicate, with highly reproducible findings, and representative data are shown. E: percent inhibition of maximal HMW-HA-induced TER response in human EC with scramble, annexin A11, annexin A2, protein S100-A10, or annexin A2 + protein S100-A10 siRNA treatment. Silencing both annexin II and protein S100-A10 is required for maximal inhibition of HMW-HA-induced TER in EC.
Techniques Used: Control, Staining, Fluorescence, SDS Page, Immunoprecipitation, Inhibition


